18575 Jamboree Road
Suite 275-S
Irvine, CA 92612
United States
858 283 0280
https://reneopharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Michael G. Grey | Founder & Executive Chairman | 100k | N/A | 1953 |
Mr. Gregory J. Flesher | President, CEO & Director | 569.7k | N/A | 1970 |
Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer | 466.23k | N/A | 1961 |
Ms. Ashley F. Hall J.D. | Chief Development Officer | 447.1k | N/A | 1972 |
Ms. Jennifer P. Lam | SVP of Finance & Administration and Principal Financial & Accounting Officer | N/A | N/A | N/A |
Mr. Michael P. Cruse | Chief Operating Officer | 535.47k | N/A | 1972 |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Reneo Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 8; Compensation: 9.